{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:23Z","timestamp":1793109743110,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40257-025-00964-6","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T04:32:33Z","timestamp":1753763553000},"page":"829-841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct03047395","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Z.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rubant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenton","family":"Bialik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"1","key":"964_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000504841","volume":"237","author":"K Callis Duffin","year":"2021","unstructured":"Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, et al. Characterization of patients with psoriasis in challenging-to-treat body areas in the Corrona Psoriasis Registry. Dermatology. 2021;237(1):46\u201355. https:\/\/doi.org\/10.1159\/000504841.","journal-title":"Dermatology"},{"issue":"3","key":"964_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3): e12589. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther"},{"issue":"4","key":"964_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000528945","volume":"239","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I, et al. Patient perspectives on psoriatic disease burden: results from the global psoriasis and beyond survey. Dermatology. 2023;239(4):621\u201334. https:\/\/doi.org\/10.1159\/000528945.","journal-title":"Dermatology"},{"issue":"1","key":"964_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","volume":"75","author":"B Strober","year":"2016","unstructured":"Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77-82.e7. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.026.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"964_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jaad.2021.12.032","volume":"88","author":"C Ryan","year":"2023","unstructured":"Ryan C, Puig L, Zema C, Thompson EHZ, Yang M, Wu E, et al. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. J Am Acad Dermatol. 2023;88(1):169\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2021.12.032.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"964_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2018.80718","volume":"56","author":"K Dopytalska","year":"2018","unstructured":"Dopytalska K, Sobolewski P, B\u0142aszczak A, Szyma\u0144ska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56(6):392\u20138. https:\/\/doi.org\/10.5114\/reum.2018.80718.","journal-title":"Reumatologia"},{"issue":"4","key":"964_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2340\/00015555-1731","volume":"94","author":"F Sampogna","year":"2014","unstructured":"Sampogna F, Linder D, Piaserico S, Altomare G, Bortune M, Calzavara-Pinton P, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94(4):411\u20134. https:\/\/doi.org\/10.2340\/00015555-1731.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"964_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2014.04.063","volume":"71","author":"J Chung","year":"2014","unstructured":"Chung J, Callis Duffin K, Takeshita J, Shin DB, Krueger GG, Robertson AD, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.063.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"964_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. https:\/\/doi.org\/10.1186\/s12895-020-00099-7.","journal-title":"BMC Dermatol"},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"1331217","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. https:\/\/doi.org\/10.3389\/fimmu.2024.1331217.","journal-title":"Front Immunol"},{"key":"964_CR11","unstructured":"Skyrizi (risankizumab-rzaa). Prescribing information. AbbVie Inc; 2024. https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf. Accessed 8 Apr 2024."},{"issue":"10148","key":"964_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6.","journal-title":"Lancet"},{"issue":"8","key":"964_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J Dermatol. 2019;46(8):686\u201394. https:\/\/doi.org\/10.1111\/1346-8138.14941.","journal-title":"J Dermatol"},{"issue":"10198","key":"964_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3.","journal-title":"Lancet"},{"issue":"1","key":"964_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjd.20481","volume":"186","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, et al. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-na\u00efve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2022;186(1):30\u20139. https:\/\/doi.org\/10.1111\/bjd.20481.","journal-title":"Br J Dermatol"},{"issue":"2","key":"964_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s13555-021-00490-3","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, de Vente S, Zeng J, Flack M, Padilla B, Tyring SK. Long-term safety and efficacy of risankizumab in patients with moderate-to-severe chronic plaque psoriasis: results from a phase 2 open-label extension trial. Dermatol Ther (Heidelb). 2021;11(2):487\u201397. https:\/\/doi.org\/10.1007\/s13555-021-00490-3.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"964_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0723.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"964_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","volume":"89","author":"KA Papp","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. 2023;89(6):1149\u201358. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1024.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"964_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/bjd.20595","volume":"185","author":"KA Papp","year":"2021","unstructured":"Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135\u201345. https:\/\/doi.org\/10.1111\/bjd.20595.","journal-title":"Br J Dermatol"},{"issue":"5","key":"964_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jdv.19748","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Bachelez H, Crowley J, Elewski BE, Gooderham M, Menter A, et al. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). J Eur Acad Dermatol Venereol. 2024;38(5):864\u201372. https:\/\/doi.org\/10.1111\/jdv.19748.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"964_CR21","first-page":"571","volume":"19","author":"KA Papp","year":"2020","unstructured":"Papp KA, Langholff W. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata. J Drugs Dermatol. 2020;19(6):571\u20132.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"964_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/bjd.14068","volume":"173","author":"AB Kimball","year":"2015","unstructured":"Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. Br J Dermatol. 2015;173(5):1183\u201390. https:\/\/doi.org\/10.1111\/bjd.14068.","journal-title":"Br J Dermatol"},{"issue":"7","key":"964_CR23","first-page":"706","volume":"14","author":"K Papp","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706\u201314.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"964_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333. https:\/\/doi.org\/10.1159\/000365390.","journal-title":"Dermatology"},{"issue":"6","key":"964_CR25","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359. https:\/\/doi.org\/10.1111\/bjd.20568.","journal-title":"Br J Dermatol"},{"issue":"2","key":"964_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","volume":"185","author":"D Tha\u00e7i","year":"2021","unstructured":"Tha\u00e7i D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323\u201334. https:\/\/doi.org\/10.1111\/bjd.19866.","journal-title":"Br J Dermatol"},{"issue":"5","key":"964_CR27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/bjd.13469","volume":"172","author":"RG Langley","year":"2015","unstructured":"Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371\u201383. https:\/\/doi.org\/10.1111\/bjd.13469.","journal-title":"Br J Dermatol"},{"issue":"2","key":"964_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2023","unstructured":"Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023;188(2):198\u2013207. https:\/\/doi.org\/10.1093\/bjd\/ljac040.","journal-title":"Br J Dermatol"},{"issue":"2","key":"964_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","volume":"85","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.022.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"964_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","volume":"10","author":"C Leonardi","year":"2020","unstructured":"Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10(3):431\u201347. https:\/\/doi.org\/10.1007\/s13555-020-00367-x.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"964_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041675","author":"M Adamczyk","year":"2023","unstructured":"Adamczyk M, Bartosi\u0144ska J, Raczkiewicz D, Adamska K, Adamski Z, Czubek M, et al. Risankizumab therapy for moderate-to-severe psoriasis-a multi-center, long-term, real-life study from Poland. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12041675.","journal-title":"J Clin Med"},{"issue":"1","key":"964_CR32","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/jdv.19464","volume":"38","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, et al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2024;38(1):e113\u20136. https:\/\/doi.org\/10.1111\/jdv.19464.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"964_CR33","doi-asserted-by":"publisher","first-page":"2425029","DOI":"10.1080\/09546634.2024.2425029","volume":"35","author":"L Ibba","year":"2024","unstructured":"Ibba L, Di Giulio S, Gargiulo L, Facheris P, Perugini C, Costanzo A, et al. Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study. J Dermatol Treat. 2024;35(1):2425029. https:\/\/doi.org\/10.1080\/09546634.2024.2425029.","journal-title":"J Dermatol Treat"},{"issue":"5","key":"964_CR34","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s13555-024-01164-6","volume":"14","author":"A Pinter","year":"2024","unstructured":"Pinter A, Soliman AM, Pivneva I, Ghanbariamin R, Yang M, Truong B, et al. Real-world long-term effectiveness of risankizumab among patients with moderate-to-severe psoriasis: analysis from an international medical chart review (RAPID) study. Dermatol Ther (Heidelb). 2024;14(5):1259\u201371. https:\/\/doi.org\/10.1007\/s13555-024-01164-6.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"964_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s13555-025-01342-0","volume":"15","author":"D Tha\u00e7i","year":"2025","unstructured":"Tha\u00e7i D, Ohtsuki M, Maul JT, Szegedi A, Luna PC, Lynde CW, et al. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis: interim analysis from the VALUE global prospective post-marketing observational study at 25 months. Dermatol Ther (Heidelb). 2025;15(2):381\u201394. https:\/\/doi.org\/10.1007\/s13555-025-01342-0.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"5","key":"964_CR36","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","volume":"80","author":"U Mrowietz","year":"2019","unstructured":"Mrowietz U, Bachelez H, Burden AD, Rissler M, Sieder C, Orsenigo R, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80(5):1344\u201352. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.066.","journal-title":"J Am Acad Dermatol"},{"key":"964_CR37","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.18672","volume":"104","author":"E Sonkoly","year":"2024","unstructured":"Sonkoly E, Maul JT, Megna M, Gorecki P, Crombag E, Buyze J, et al. Guselkumab in patients with scalp psoriasis: a post hoc analysis of the VOYAGE 2 phase III randomized clinical trial. Acta Derm Venereol. 2024;104: adv18672. https:\/\/doi.org\/10.2340\/actadv.v104.18672.","journal-title":"Acta Derm Venereol"},{"issue":"16","key":"964_CR38","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1607017.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00964-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00964-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00964-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:03:18Z","timestamp":1757966598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00964-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00964-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"23 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by AbbVie, Inc. (North Chicago, IL, USA). AbbVie participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of this publication. No honoraria or payments were made for authorship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"KAP has received honoraria and\/or grants from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO, Lilly, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab. MGL is an employee of Mount Sinai and received research funds from AbbVie, Aikium, Almirall, AltruBio, Amgen, Apogee, Arcutis, AstraZeneca, Atomwise, Avotres, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celltrion, Clexio, CorEvitas, Dermavant, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, Inozyme, LEO, Lilly, Johnson & Johnson, Mayne, Meiji Seika, Mindera, Mirium, Oruka, Pfizer, Revolo, Sanofi-Regeneron, Seanergy, Strata, Sun Pharma, Takeda, Trevi, UCB, and Verrica. He also serves as an Editorial Board member of the American Journal of Clinical Dermatology and was not involved in the selection of peer reviewers for the manuscript, nor any of the subsequent editorial decisions. LP has received consultancy fees, speaker\u2019s fees, or fees for participating in clinical trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Boehringer Ingelheim, Biogen, Celgene, EMD Serono, Gebro, Janssen, LEO, Lilly, Merck, Mylan, Novartis, Pfizer, Regeneron, Roche, Samsung Bioepis, Sandoz, Sanofi, and UCB. MO has received honoraria for participating on advisory boards, serving on speakers\u2019 bureaus and consulting, as well as grants for investigator activities from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Janssen, Kyowa Kirin, LEO, Lilly, Maruho, Mitsubishi Tanabe, Novartis, Pfizer, Sun, Taiho, Torii, and UCB. SB has received honoraria as an advisory board member and\/or speaker for AbbVie, Actelion, Almirall, Amgen, Bristol Myers Squibb, Celgene, Galderma, GSK, Janssen, LEO, Lilly, Menlo, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. MG is or has been an investigator, adviser, and\/or speaker for AbbVie, Akros, Amgen, AnaptysBio, Arcutis, Aristea, Bausch, Boehringer Ingelheim, Bristol Myers Squibb, Coherus BioSciences, Dermavant, Dermira, Galderma, GlaxoSmithKline, JAMP, Janssen, Kyowa Kirin, LEO, Lilly, Medimmune, Meiji, Merck, Moonlake, Nimbus, Novartis, Oruka, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, UCB, Ventyx, and Vyne. AZA is a consultant and speaker for AbbVie, Amgen, Janssen, Lilly, Pfizer, Sanofi Genzyme, and UCB. TW, SR, BB, DA, AMS, and MMC are full-time employees of AbbVie Inc., and may hold AbbVie stock, stock options, and\/or patents. AB has served as a speaker (received honoraria) for Almirall, Lilly, and UCB. He has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, LEO, Lilly, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, Union, and Zai Lab. He also has served as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, LEO, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB. He owns stock in Lipidio and Oruka.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal, statistical analysis plan (SAP), and execution of a data sharing agreement (DSA). Data requests can be submitted at any time after approval in the United States and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:  then select \u201cHome.\u201d","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All patients provided written informed consent before study initiation. The study protocol adhered to the Declaration of Helsinki, International Conference for Harmonisation guidelines, and other relevant regulations. The study was approved by central (Advarra IRB Services, Columbia, MD, USA) and local, independent ethics committees and\/or institutional review boards at each participating study site.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KAP, MGL, LP, MO, SB, SR, and AB contributed to the conception and design of the work. KAP, MGL, LP, MO, SB, SR, AB, and TW contributed to data acquisition. TW, SR, BB, DA, AMS, and MMC contributed to the analysis of the data. All authors contributed to interpretation of the data. All authors had access to relevant data and participated in the drafting, review, and approval of this publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}